Tenax Therapeutics/ US88032L6056 /
2024-05-10 9:57:38 PM | Chg. -0.03 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
3.55USD | -0.84% | 255 Turnover: 909.39 |
-Bid Size: - | -Ask Size: - | 3.62 | 3.49 |
GlobeNewswire
04-30
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertens...
GlobeNewswire
04-09
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a...
GlobeNewswire
03-28
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial ...
GlobeNewswire
02-29
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT ...
GlobeNewswire
02-20
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimen...
GlobeNewswire
02-08
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
GlobeNewswire
02-08
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimenda...
GlobeNewswire
02-06
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significa...
GlobeNewswire
2023-11-17
Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific ...
GlobeNewswire
2023-11-13
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment ...
GlobeNewswire
2022-01-04
Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs